FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group - Concepedia

Concepedia

Publication | Closed Access

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

86

Citations

23

References

2022

Year

Ralf‐Dieter Hofheinz, Kirsten Merx, Georg Martin Haag, Christoph Springfeld, Thomas J. Ettrich, K Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Margareta Siegler, Matthias P. Ebert,

Journal of Clinical Oncology

Abstract

The addition of trastuzumab/pertuzumab to perioperative FLOT significantly improved pCR and nodal negativity rates at the price of higher rates of diarrhea and leukopenia.

References

	Year	Citations

Page 1